Advanced search
Publication Cover
Expert Review of Cardiovascular Therapy Volume 3, 2005 - Issue 4
Submit an article Journal homepage
36
Views
4
CrossRef citations to date
0
Altmetric
Drug Profile

Ximelagatran for stroke prevention in atrial fibrillation

Christopher J Boos City Hospital, Haemostasis, Thrombosis and Vascular Biology Unit, University Department of Medicine, Birmingham B18 7QH, UK
&
Gregory YH Lip City Hospital, Haemostasis, Thrombosis and Vascular Biology Unit, University Department of Medicine, Birmingham B18 7QH, UK. [email protected]
Pages 551-563 | Published online: 10 Jan 2014

References

  • Singer DE, Albers GW, Dalen JE, Go AS, Halperin JL, Manning WJ. Antithrombotic therapy in atrial fibrillation: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 126(Suppl.), 429S–456S (2004).
  • Fuster V, Ryden LE, Asinger RW et al. ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation: executive summary a report of the American College of Cardiology/American Heart Association task force on practice guidelines and the European Society of Cardiology committee for practice guidelines and policy conferences (committee to develop guidelines for the management of patients with atrial fibrillation) developed in collaboration with the North American Society of Pacing and Electrophysiology. Circulation 104, 2118–2150 (2001).
  • Gronefeld GC, Hohnloser SH. Heart failure complicated by atrial fibrillation: mechanistic, prognostic, and therapeutic implications. J. Cardiovasc. Pharmacol. Ther. 8, 107–113 (2003).
  • Kilander L, Andren B, Nyman H, Lind L, Boberg M, Lithell H. Atrial fibrillation is an independent determinant of low cognitive function: a cross-sectional study in elderly men. Stroke29, 1816–1820 (1998).
  • Benjamin EJ, Levy D, Vaziri SM, D’agostino RB, Belanger AJ, Wolf PA. Independent risk factors for atrial fibrillation in a population-based cohort. The Framingham Heart Study. JAMA 271, 840–844 (1994).
  • Kannel WB, Wolf PA, Benjamin EJ, Levy D. Prevalence, incidence, prognosis, and predisposing conditions for atrial fibrillation: population-based estimates. Am. J. Cardiol. 82, 2N–9N (1998).
  • Go AS, Hylek EM, Phillips KA et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the anticoagulation and risk factors in atrial fibrillation (atria) study. JAMA 285, 2370–2375 (2001).
  • Steinberg JS. Atrial fibrillation: an emerging epidemic? Heart 90, 239–234 (2004).
  • Stewart S, Murphy N, Walker A, McGuire A, McMurray JJ. Cost of an emerging epidemic: an economic analysis of atrial fibrillation in the UK. Heart 90, 286–292 (2004).
  • Tsang TS, Petty GW, Barnes ME et al. The prevalence of atrial fibrillation in incident strokecases and matched population controls in Rochester, Minnesota: changes over three decades. J. Am. Coll. Cardiol. 42, 93–100 (2003).
  • Chugh SS, Blackshear JL, Shen WK, Hammill SC, Gersh BJ. Epidemiology and natural history of atrial fibrillation: clinical implications. J. Am. Coll. Cardiol. 37, 371–378 (2001).
  • Howard VJ, Acker J, Gomez CR et al. An approach to co-ordinate efforts to reduce the public health burden of stroke: the Delta States Stroke Consortium. Prev. Chronic Dis. 1, A19 (2004).
  • Alonso de Lecinana-Cases M, Perez-R GE, Diez-Tejedor E. Recommendations for stroketreatment and prevention, 2004. Sociedad Iberoamericana de Envermedad Cerobrovascular (SIECV). Rev. Neurol. 39, 465–486 (2004).
  • Manning WJ, Silverman DI, Waksmonski CA, Oettgen P, Douglas PS. Prevalence of residual left atrial thrombi among patients with acute thromboembolism and newly recognized atrial fibrillation. Arch. Intern. Med. 155, 2193–2198 (1995).
  • Lamassa M, Di Carlo A, Pracucci G et al. Characteristics, outcome, and care of stroke associated with atrial fibrillation in Europe: data from a multicenter multinational hospital-based registry (The European Community Stroke Project). Stroke32, 392–398 (2001).
  • Lin HJ, Wolf PA, Kelly-Hayes M et al. Stroke severity in atrial fibrillation. The Framingham Study. Stroke27, 1760–1764 (1996).
  • Hohnloser SH, Kuck KH, Lilienthal J. Rhythm or rate control in atrial fibrillation – Pharmacological Intervention in Atrial Fibrillation (PIAF), a randomised trial. Lancet 356, 1789–1794 (2000).
  • Van Gelder IC, Hagens VE, Bosker HA et al. A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. Rate Control versus Electrical Cardioversion for Persistent Atrial Fibrillation Study Group. N. Engl. J. Med. 347, 1834–1840 (2002).
  • Wyse DG, Waldo AL, DiMarco JP et al. A comparison of rate control and rhythm control in patients with atrial fibrillation. Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) Investigators. N. Engl. J. Med. 347, 1825–1833 (2002).
  • Carlsson J, Miketic S, Windeler J et al. Randomized trial of rate-control versus rhythm-control in persistent atrial fibrillation: the Strategies of Treatment of Atrial Fibrillation (STAF) study. STAF Investigators. J. Am. Coll. Cardiol. 41, 1690–1696 (2003).
  • Opolski G, Torbicki A, Kosior DA et al. Rate control vs. rhythm control in patients with nonvalvular persistent atrial fibrillation: the results of the Polish How to Treat Chronic Atrial Fibrillation (HOT CAFE) Study. Investigators of the Polish HOT CAFE Study. Chest 126, 476–486 (2004).
  • Peterson P, Boysen G, Gofriedsen J, Andersen ED, Anderson B. Placebo-controlled, randomized trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation: the Copenhagen AFASAK Study. Lancet 1, 175–179 (1989).
  • StrokePrevention in Atrial Fibrillation (SPAF) Investigators. Stroke prevention in atrial fibrillation study: final results. Circulation 84, 527–539 (1991).
  • The Boston Area Anticoagulation Trial for Atrial Fibrillation (BAATAF) Investigators. The effect of low-dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation. N. Engl. J. Med. 323, 1505–1511 (1990).
  • Ezekowitz MD, Bridgers SL, James KE et al. Warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation (SPINAF). N. Engl. J. Med. 327, 1406–1412 (1992).
  • Connolly SJ, Laupacis A, Gent M, Roberts RS, Cairns JA, Joyner C. Canadian Atrial Fibrillation Anticoagulation (CAFA) Study. J. Am. Coll. Cardiol. 18, 349–355 (1991).
  • Atrial Fibrillation Investigators. Risk factors for stroke and efficiency of antithrombotic therapy in atrial fibrillation analysis of pooled data from five randomized controlled trials. Arch. Intern. Med. 154, 1449–1457 (1994).
  • European Atrial Fibrillation (EAFT) Study Group. Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke. Lancet 342, 1255–1262 (1993).
  • Perret-Guillaume C, Wahl DG. Low-dose warfarin in atrial fibrillation leads to more thromboembolic events without reducing major bleeding when compared to adjusted-dose – a meta-analysis. Thromb. Haemost. 91, 394–402 (2004).
  • Perez-Gomez F, Alegria E, Berjon J et al. Comparative effects of antiplatelet, anticoagulant, or combined therapy in patients with valvular and nonvalvular atrial fibrillation: a randomized multicenter study. NASPEAF Investigators. J. Am. Coll. Cardiol. 44, 1557–1566 (2004).
  • Li-Saw-Hee FL, Blann AD, Lip GY. Effects of fixed low-dose warfarin, aspirin-warfarin combination therapy, and dose-adjusted warfarin on thrombogenesis in chronic atrial fibrillation. Stroke31, 828–833 (2000).
  • Hart RG, Benavente O, McBride R, Pearce LA. Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a meta-analysis. Ann. Intern. Med. 131, 492–501 (1999).
  • Van Walraven C, Hart RG, Singer DE et al. Oral anticoagulants vs. aspirin in nonvalvular atrial fibrillation: an individual patient meta-analysis. JAMA 288, 2441–2448 (2002).
  • Ansell J, Hirsh J, Poller L, Bussey H, Jacobson A, Hylek E. The pharmacology and management of the vitamin K antagonists: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 126(Suppl. 3), 204S–233S (2004).
  • Fang MC, Chang Y, Hylek EM et al. Advanced age, anticoagulation intensity, and risk for intracranial hemorrhage among patients taking warfarin for atrial fibrillation. Ann. Intern. Med. 141, 745–752 (2004).
  • Easton JD. Evidence with antiplatelet therapy and ADP-receptor antagonists. Cerebrovasc. Dis. 16(Suppl. 1), 20–26 (2003).
  • Patrono C, Coller B, Dalen JE et al. Platelet-active drugs: the relationships among dose, effectiveness, and side effects. Chest 119, 39S–63S (2001).
  • Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators. N. Engl. J. Med. 345, 494–502 (2001).
  • Diener HC, Cunha L, Forbes C, Sivenius J, Smets P, Lowenthal A. European Stroke Prevention Study 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. J. Neurol. Sci. 143, 1–13 (1996).
  • Lorenzoni R, Lazzerini G, Cocci F, De Caterina R. Short-term prevention of thromboembolic complications in patients with atrial fibrillation with aspirin plus clopidogrel: the Clopidogrel–Aspirin Atrial Fibrillation (CLAAF) pilot study. Am. Heart J 148, E6 (2004).
  • Hohnloser SH, Connolly SJ. Combined antiplatelet therapy in atrial fibrillation: review of the literature and future avenues. J. Cardiovasc. Electrophysiol. 14(Suppl. 9), S60–S63 (2003).
  • Diener HC, Bogousslavsky J, Brass LM et al. Management of atherothrombosis with clopidogrel in high-risk patients with recent transient ischaemic attack or ischaemic stroke (MATCH), study design and baseline data. Cerebrovasc. Dis. 17, 253–261 (2004).
  • Diener HC, Bogousslavsky J, Brass LM et al. Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH), randomised, double-blind, placebo-controlled trial. MATCH investigators. Lancet 364, 331–337 (2004).
  • Jaffer A, Bragg L. Practical tips for warfarin dosing and monitoring. Cleve. Clin. J. Med. 70, 361–371 (2003).
  • Aithal GP, Day CP, Kesteven PJ, Daly AK. Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications. Lancet 353, 717–719 (1999).
  • Donnan GA, Dewey HM, Chambers BR. Warfarin for atrial fibrillation: the end of an era? Lancet Neurol. 3, 305–308 (2004).
  • Haustein KO. Pharmacokinetic and pharmacodynamic properties of oral anticoagulants, especially phenprocoumon. Semin. Thromb. Hemost. 25, 5–11 (1999).
  • Tabrizi AR, Zehnbauer BA, Borecki IB, McGrath SD, Buchman TG, Freeman BD. The frequency and effects of cytochrome P450 (CYP) 2C9 polymorphisms in patients receiving warfarin. J. Am. Coll. Surg. 194, 267–273 (2002).
  • Tabrizi AR, Zehnbauer BA, Borecki IB, McGrath SD, Buchman TG, Freeman BD. Role of dietary vitamin K intake in chronic oral anticoagulation: prospective evidence from observational and randomized protocols. Am. J. Med. 116, 651–656 (2004).
  • Hylek EM, Skates SJ, Sheehan MA, Singer DE. An analysis of the lowest effective intensity of prophylactic anticoagulation for patients with nonrheumatic atrial fibrillation. N. Engl. J. Med. 335, 540–546 (1996).
  • Reynolds MW, Fahrbach K, Hauch O et al. Warfarin anticoagulation and outcomes in patients with atrial fibrillation: a systematic review and metaanalysis. Chest 126, 1938–1945 (2004).
  • Levine MN, Raskob G, Beyth RJ, Kearon C, Schulman S. Hemorrhagic complications of anticoagulant treatment: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 126(Suppl. 3), 287S–310S (2004).
  • Hylek EM, Go AS, Chang Y et al. Effect of intensity of oral anticoagulation on strokeseverity and mortality. N. Engl. J. Med. 349, 1019–1026 (2003).
  • Hylek EM, Singer DE. Risk factors for intracranial hemorrhage in out-patients taking warfarin. Ann. Intern. Med. 120, 897–902 (1994).
  • McCormick D, Gurwitz JH, Goldberg RJ et al. Prevalence and quality of warfarin use for patients with atrial fibrillation in the long-term care setting. Arch. Intern. Med. 161, 2458–2463 (2001).
  • Smith NL, Psaty BM, Furberg CD et al. Temporal trends in the use of anticoagulants among older adults with atrial fibrillation. Arch. Intern. Med. 159, 1574–1578 (1999).
  • Fang MC, Stafford RS, Ruskin JN, Singer DE. National trends in anti-arrhythmic and antithrombotic medication use in atrial fibrillation. Arch. Intern. Med. 164, 55–60 (2004).
  • Nadar S, Begum N, Kaur B, Sandhu S, Lip GY. Patients’ understanding of anticoagulant therapy in a multiethnic population. J. R. Soc. Med. 96, 175–179 (2003).
  • Bungard TJ, Ghali WA, Teo KK, McAlister FA, Tsuyuki RT. Why do patients with atrial fibrillation not receive warfarin? Arch. Intern. Med. 160, 41–46 (2000).
  • Lip GY, Kamath S, Jafri M, Mohammed A, Bareford D. Ethnic differences in patient perceptions of atrial fibrillation and anticoagulation therapy: the West Birmingham Atrial Fibrillation Project. Stroke33, 238–242 (2002).
  • Gustafsson D, Nystrom J, Carlsson S et al. The direct thrombin inhibitor melagatran and its oral prodrug H 376/95, intestinal absorption properties, biochemical and pharmacodynamic effects. Thromb. Res. 101, 171–181 (2001).
  • Eriksson UG, Bredberg U, Gislen K et al. Pharmacokinetics and pharmacodynamics of ximelagatran, a novel oral direct thrombin inhibitor, in young healthy male subjects. Eur. J. Clin. Pharmacol. 59, 35–43 (2003).
  • Eriksson UG, Bredberg U, Hoffmann KJ et al. Absorption, distribution, metabolism, and excretion of ximelagatran, an oral direct thrombin inhibitor, in rats, dogs, and humans. Drug Metab. Dispos. 31, 294–305 (2003).
  • Johansson LC, Frison L, Logren U, Fager G, Gustafsson D, Eriksson UG. Influence of age on the pharmacokinetics and pharmacodynamics of ximelagatran, an oral direct thrombin inhibitor. Clin. Pharmacokinet. 42, 381–392 (2003).
  • Eriksson H, Eriksson UG, Frison L et al. Pharmacokinetics and pharmacodynamics of melagatran, a novel synthetic LMW thrombin inhibitor, in patients with acute DVT. Thromb. Haemost. 81, 358–363 (1999).
  • Wolzt M, Wollbratt M, Svensson M, Wahlander K, Grind M, Eriksson UG. Consistent pharmacokinetics of the oral direct thrombin inhibitor ximelagatran in patients with nonvalvular atrial fibrillation and in healthy subjects. Eur. J. Clin. Pharmacol. 59, 537–543 (2003).
  • Dager WE, Vondracek TG, McIntosh BA, Nutescu EA. Ximelagatran: an oral direct thrombin inhibitor. Ann. Pharmacother. 38, 1881–1897 (2004).
  • Eriksson UG, Johansson S, Attman PO et al. Influence of severe renal impairment on the pharmacokinetics and pharmacodynamics of oral ximelagatran and subcutaneous melagatran. Clin. Pharmacokinet. 42, 743–753 (2003).
  • Eriksson UG. Exanta (ximelagatran) – product information on file AstraZeneca. Clin. Pharm. 42, 687–701 (2003).
  • Johansson LC, Andersson M, Fager G, Gustafsson D, Eriksson UG. No influence of ethnic origin on the pharmacokinetics and pharmacodynamics of melagatran following oral administration of ximelagatran, a novel oral direct thrombin inhibitor, to healthy male volunteers. Clin. Pharmacokinet. 42, 475–484 (2003).
  • Sarich TC, Teng R, Peters GR et al. No influence of obesity on the pharmacokinetics and pharmacodynamics of melagatran, the active form of the oral direct thrombin inhibitor ximelagatran. Clin. Pharmacokinet. 42, 485–492 (2003).
  • Gustafsson D, Elg M. The pharmacodynamics and pharmacokinetics of the oral direct thrombin inhibitor ximelagatran and its active metabolite melagatran: a mini-review. Thromb. Res. 109(Suppl.), S9–S15 (2003).
  • Crowther MA, Weitz JI. Ximelagatran: the first oral direct thrombin inhibitor. Expert Opin. Investig. Drugs 13, 403–413 (2004).
  • Fager G, Cullberg M, Eriksson- Lepkowska M, Frison L, Eriksson UG. Pharmacokinetics and pharmacodynamics of melagatran, the active form of the oral direct thrombin inhibitor ximelagatran, are not influenced by acetylsalicylic acid. Eur. J. Clin. Pharmacol. 59, 283–289 (2003).
  • Wahlander K, Eriksson-Lepkowska M, Frison L, Fager G, Eriksson UG. No influence of mild-to-moderate hepatic impairment on the pharmacokinetics and pharmacodynamics of ximelagatran, an oral direct thrombin inhibitor. Clin. Pharmacokinet. 42, 755–764 (2003).
  • Bredberg E, Andersson TB, Frison L et al. Ximelagatran, an oral direct thrombin inhibitor, has a low potential for cytochrome P450-mediated drug–drug interactions. Clin. Pharmacokinet. 42, 765–777 (2003).
  • Sarich TC, Johansson S, Schutzer KM et al. The pharmacokinetics and pharmacodynamics of ximelagatran, an oral direct thrombin inhibitor, are unaffected by a single dose of alcohol. J. Clin. Pharmacol. 44, 388–393 (2004).
  • Sarich TC, Schutzer KM, Wollbratt M, Wall U, Kessler E, Eriksson UG. No pharmacokinetic or pharmacodynamic interaction between digoxin and the oral direct thrombin inhibitor ximelagatran in healthy volunteers. J. Clin. Pharmacol. 44, 935–941 (2004).
  • Teng R, Sarich TC, Eriksson UG et al. A pharmacokinetic study of the combined administration of amiodarone and ximelagatran, an oral direct thrombin inhibitor. J. Clin. Pharmacol. 44, 1063–1071 (2004).
  • Sarich TC, Schutzer KM, Dorani H et al. No pharmacokinetic or pharmacodynamic interaction between atorvastatin and the oral direct thrombin inhibitor ximelagatran. J. Clin. Pharmacol. 44, 928–934 (2004).
  • Dorani H, Schutzer K, Wollbratt M et al. No clinically significant interaction between the oral direct thrombin inhibitor ximelagatran and amiodarone, atorvastatin, or digoxin. Clin. Pharmacol. Therapeut. 75, 78 (2004) (Abstract PII-98).
  • Dorani H, Schutzer K, Sarich T et al. Effect of erythromycin on the pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor ximelagatran and its active form melagatran. Clin. Pharmacol. Therapeut. 75, 78 (2004) (Abstract PII-99).
  • Dorani H, Schützer K, Sarich T, Wall U, Ohlsson L, Eriksson U. No effect of amoxicillin, doxycycline, and ciprofloxacin on the pharmacokinetics and pharmacodynamics of ximelagatran. Clin. Pharmacol. Therapeut. 77, 46 (2005) (Abstract PI-147).
  • Dorani H, Schützer K, Sarich T, Wall U, Ohlsson L, Eriksson U. The pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor ximelagatran when administered with azithromycin and cefuroxime. Clin. Pharmacol. Therapeut. 77, 83 (2005) (Abstract PII-126).
  • Samama MM, Gerotziafas GT, Elalamy I, Horellou MH, Conard J. Biochemistry and clinical pharmacology of new anticoagulant agents. Pathophysiol. Haemost. Thromb. 32, 218–24 (2002).
  • Weitz JI. A novel approach to thrombin inhibition. Thromb. Res. 109(Suppl. 1), S17–S22 (2003).
  • Elg M, Gustafsson D, Carlsson S. Antithrombotic effects and bleeding time of thrombin inhibitors and warfarin in the rat. Thromb. Res. 94, 187–197 (1999).
  • Fager G, Cullberg M, Eriksson- Lepkowska M, Frison L, Eriksson UG. Pharmacokinetics and pharmacodynamics of melagatran, the active form of the oral direct thrombin inhibitor ximelagatran, are not influenced by acetylsalicylic acid. Eur. J. Clin. Pharmacol. 59, 283–289 (2003).
  • Elg M, Carlsson S, Gustafsson D. Effects of agents, used to treat bleeding disorders, on bleeding time prolonged by a very high dose of a direct thrombin inhibitor in anesthesized rats and rabbits. Thromb. Res. 101, 159–170 (2001).
  • Elg M, Carlsson S, Gustafsson D. Effect of activated prothrombin complex concentrate or recombinant Factor VIIa on the bleeding time and thrombus formation during anticoagulation with a direct thrombin inhibitor. Thromb. Res. 101, 145–157 (2001).
  • Carlsson SC, Mattsson C, Eriksson UG et al. A review of the effects of the oral direct thrombin inhibitor ximelagatran on coagulation assays. Thromb. Res. 115, 9–18 (2005).
  • Mattsson C, Menschiek-Lundin A, Wahlander K, Lindahl TL. Effect of melagatran on prothrombin time assays depends on the sensitivity of the thromboplastin and the final dilution of the plasma sample. Thromb. Haemost. 86, 611–615 (2001).
  • Gruber A, Carlsson S, Kotze H et al. Activated Factor VII is hemostatic without promoting thrombus propagation. Blood 102(11), 809 (2003) (Abstract 2998) .
  • Reiffel JA. The potential for changing prescribing patterns from warfarin to oral direct thrombin inhibitors: clinical scenarios. Rev. Cardiovasc. Med. 5(Suppl. 5), S12–S21 (2004).
  • Halperin JL. Executive Steering Committee, SPORTIF III and V Study Investigators. Ximelagatran compared with warfarin for prevention of thromboembolism in patients with nonvalvular atrial fibrillation: rationale, objectives, and design of a pair of clinical studies and baseline patient characteristics (SPORTIF III and V). Am. Heart J. 146, 431–438 (2003).
  • Petersen P, Grind M, Adler J. Ximelagatran versus warfarin for Stroke prevention in patients with nonvalvular atrial fibrillation. SPORTIF II: a dose-guiding, tolerability, and safety study. SPORTIF II Investigators. J. Am. Coll. Cardiol. 41, 1445–1451 (2003).
  • Petersen P. StrokePrevention using an Oral Thrombin Inhibitor in atrial Fibrillation (SPORTIF) IV. Neurology 58(Suppl. 3), A477 (2002).
  • Olsson SB. Strokeprevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III), randomised controlled trial. Executive Steering Committee on behalf of the SPORTIF III Investigators. Lancet 362, 1691–1698 (2003).
  • SPORTIF Executive Committee for the SPORTIF V Investigators. Ximelagatran versus warfarin for strokeprevention in patients with nonvalvular atrial fibrillation. JAMA 293, 690–698 (2005).
  • Albers GW, for the Executive Steering Committee on behalf of the SPORTIF Investigators. Pooled analysis of the SPORTIF III and V trials: secondary stroke prevention and stroke subtypes. Stroke35, 242–243 (2004).
  • Diener HC. Strokeprevention with the oral direct thrombin inhibitor ximelagatran in patients with nonvalvular atrial fibrillation: pooled analysis of the SPORTIF III and V trials. Stroke17(Suppl. 5) (2004) (Abstract 16).
  • Halperin JL. Ximelagatran: oral direct thrombin inhibition as anticoagulant therapy in atrial fibrillation. J. Am. Coll. Cardiol. 45, 1–9 (2005).
  • O’Brien CL, Gage BF.Costs and effectiveness of ximelagatran for stroke prophylaxis in chronic atrial fibrillation. JAMA 293, 699–706 (2005).
  • Gurewich V. Ximelagatran – promises and concerns. JAMA 293, 736–739 (2005).
  • Hamaad A, Tayebjee MH, Lip GYH. The METHRO (MElagatran for THRombin inhibition in Orthopaedic surgery) trials. Expert Opin. Investig. Drugs 12, 865–870 (2003).
  • Eriksson BI, Bergqvist D, Kalebo P et al. Direct thrombin inhibitor melagatran followed by oral ximelagatran in comparison with enoxaparin for the prevention of venous thromboembolism after total hip or knee replacement. METHRO III Study Group. Thromb. Haemost. 89, 288–296 (2003).
  • Colwell CW Jr, Berkowitz SD, Davidson BL et al. Comparison of ximelagatran, an oral direct thrombin inhibitor, with enoxaparin for the prevention of venous thromboembolism following total hip replacement. A randomised, double-blind study. J. Thromb. Haemost.1, 2119–2130 (2003).
  • Glynn O. The express study: preliminary results. Int. J. Clin. Pract. 57, 57–59 (2003).
  • Eriksson BI, Agnelli G, Cohen AT et al. The direct thrombin inhibitor melagatran followed by oral ximelagatran compared with enoxaparin for the prevention of venous thromboembolism after total hip or knee replacement. The EXPRESS study. J. Thromb. Haemost. 1, 2490–2496 (2003).
  • Francis CW, Berkowitz SD, Comp PC et al. Comparison of ximelagatran with warfarin for the prevention of venous thromboembolism after total knee replacement. EXULT A Study Group. N. Engl. J. Med. 349, 1703–1712 (2003).
  • Colwell CW, Berkowitz SD, Comp PC et al. Randomized, double-blind comparison of ximelagatran, an oral direct thrombin inhibitor, and warfarin to prevent venous thromboembolism (VTE) after total knee replacement (TKR), EXULT B. Blood 102 (2003) (Abstract 39).
  • Francis CW, Davidson BL, Berkowitz SD et al. Ximelagatran versus warfarin for the prevention of venous thromboembolism after total knee arthroplasty. A randomized, double-blind trial. Ann. Intern. Med. 137, 648–655 (2002).
  • Schulman S, Wahlander K, Lundstrom T, Clason SB, Eriksson H. Secondary prevention of venous thromboembolism with the oral direct thrombin inhibitor ximelagatran. THRIVE III Investigators. N. Engl. J. Med. 349, 1713–1721 (2003).
  • Eriksson H, Wahlander K, Gustafsson D, Welin LT, Frison L, Schulman S. A randomized, controlled, dose-guiding study of the oral direct thrombin inhibitor ximelagatran compared with standard therapy for the treatment of acute deep vein thrombosis: THRIVE I. THRIVE Investigators. J. Thromb. Haemost. 1, 41–47 (2003).
  • Fiessinger JN, Huisman MV, Davidson BL et al. Ximelagatran vs. low molecular-weight-heparin and wargfarin for the treatment of deep vein thrombosis. THRIVE Treatment Study Investigators. JAMA 293, 681–689 (2005).
  • Wallentin L, Wilcox RG, Weaver WD et al. Oral ximelagatran for secondary prophylaxis after myocardial infarction: the ESTEEM randomised controlled trial. ESTEEM Investigators. Lancet 362, 789–797 (2003).
  • Lee WM, Larrey D, Olsson R et al. Hepatic findings in long-term clinical trials of ximelagatran. Drug Saf. 28, 351–370 (2005).
  • Christersson C, Oldgren J, Bylock A, Wallentin L, Siegbahn A. Sustained reduction in coagulation activity by long-term ximelagatran treatment after a myocardial infarction. Eur. Soc. Cardiol. August, 2004 (Abstract P3090).
  • Zimmerman HJ, Kendler J, Libber S, Lukacs L. Hepatocyte suspensions as a model for demonstration of drug hepatotoxicity. Biochem. Pharmacol. 23, 2187–2189 (1974).
  • Zimmerman HJ. Hepatoxicity: the adverse effects of drugs and other chemicals on the liver. In: Drug-induced Liver Disease. Marcel Dekker, NY, USA 16, 739–754 (1979).
  • Ascani A, Iorio A, Agnelli G. Withdrawal of warfarin after deep vein thrombosis: effects of a low fixed dose on rebound thrombin generation. Blood Coag. Fibrinol. 10(5), 291–295 (1995).
  • Iqbal MB, Taneja AK, Lip GY, Flather M. Recent developments in atrial fibrillation. Br. Med. J. 29, 238–243 (2005).

Websites

  • Exanta® (ximelgatran) tablets. FDA Advisory Committee Briefing Document Cardiovascular and Renal Drugs Advisory Committee. 10th September 2004 www.fda.gov/ohrms/dockets/ac/04/briefing/ 2004–4069B1_01_AstraZeneca-Backgrounder.pdf (Accessed June 2005)
  • The FDA’s Cardiovascular and renal Drug Advisory Committee rejects AstraZeneca’s Exanta. 10th September 2004 www.trends-in-medicine.com/ Sept2004/Sept2004.html (Accessed June 2005)
  • Astrazeneca receives action letter from FDA for Exanta® (ximelagatran). 11th October 2004 www.astrazeneca.com/pressrelease/3285.aspx (Accessed June 2005)
  • Further clinical information requested on Exanta® (ximelagatran) for the prevention of Stroke in patients with atrial fibrillation in europe. 19 January 2005 www.astrazeneca.com/pressrelease/4644.aspx (Accessed June 2005)

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.